Raymond James Financial
PDSB icon

Raymond James Financial’s PDS Biotechnology PDSB Stock Holding History

Raymond James Financial’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.19K Sell
10,236
-3,500
-25% -$2.63K ﹤0.01% 5268
2025
Q4 		$10.6K Sell
13,736
-40
-0.3% -$36 ﹤0.01% 5136
2025
Q3 		$13.9K Sell
13,776
-89
-0.6% -$105 ﹤0.01% 4922
2025
Q2 		$18.4K Sell
13,865
-100
-0.7% -$136 ﹤0.01% 5633
2025
Q1 		$16.6K Sell
13,965
-1,900
-12% -$2.7K ﹤0.01% 4733
2024
Q4 		$25.9K Buy
+15,865
New +$42K ﹤0.01% 4693

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Raymond James Financial's PDSB Position: Q1 2026 in Review

Raymond James Financial reduced its PDS Biotechnology (PDSB) stake by 25% in Q1 2026, selling an estimated $2.63K and leaving 10,236 shares worth $6.19K. The position accounts for ﹤0.01% of the portfolio, ranked #5268.

Raymond James Financial first reported a position in PDSB in Q4 2024 and has held it in 6 quarters since. The position peaked at $25.9K in Q4 2024. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

  • Raymond James Financial held 10,236 shares of PDS Biotechnology worth $6.19K as of Q1 2026.
  • Raymond James Financial sold 3,500 PDS Biotechnology shares in Q1 2026, an estimated $2.63K.
  • PDS Biotechnology made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5268 holding.
  • Raymond James Financial first reported a position in PDS Biotechnology in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's PDS Biotechnology position peaked at $25.9K in Q4 2024.
  • 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.